«Metastatic brain tumors — often from lung, breast or skin cancers — are the most commonly observed tumors within the brain and account for about 40
percent of advanced melanoma metastases.
Approximately 50
percent of advanced melanoma tumors are driven to grow by the presence of BRAF mutations and another 20 percent by the presence of NRAS mutations.
Not exact matches
The first such drug, called ipilimumab (Yervoy), developed out
of Allison's basic science research, showed much lower response rates against
advanced melanoma than those obtained with targeted drugs, but long - term follow - up found that 22
percent of those treated with Yervoy survived at least four years, unprecedented results for the disease.
According to Herlyn, these slow - growing JARID1B cells represent only one to five
percent of the cells in a tumor, yet readily divide into the fast - growing cells that are the hallmark
of advanced melanoma.
An anti-PD-1 antibody developed by Bristol - Myers Squibb generates excitement with results from a phase I trial showing that, among 236 patients with various types
of cancer, the treatment shrank tumors in 28
percent of melanoma patients, 30
percent of patients with kidney cancer, and 18
percent of patients with
advanced non-small cell lung cancer.